The US FDA is planning to withdraw its existing guidance on the development of pain products and replace it with more specific documents as part of the agency's efforts to combat the opioid crisis.
FDA has discussed the idea of additional guidance previously, but Commissioner Scott Gottlieb offered the most details to date in...




